Bayer's Sunharbo Green Light Shifts the Debate From Pipeline Promise to Profit Proof - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
Bayer investors have spent the past week weighing two very different kinds of news: a regulatory milestone for its pharmaceutical arm and a courtroom reprieve for its embattled crop-science division. The market's reaction has been split down the middle, with two major research houses landing on opposite sides of the same stock. Jefferies reiterated its "Hold" rating on Bayer with a price target of EUR 48.50, a level the shares have already left behind - the stock was trading at EUR 56.70. Deutsche Bank Research, by contrast, raised its target from EUR 60 to EUR 65 and stuck with its "Buy" recommendation, placing its mark comfortably above the current quote. The more consequential development came on Monday, when the FDA cleared SUNHARBO, whose active ingredient is asundexian, for reducing stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The approval covers use in combination with an antiplatelet therapy. Bayer expects shipments to begin between mid- and late November. The company bills the drug as the world's first approved factor XIa inhibitor, a designation underpinned by the Phase III OCEANIC-STROKE trial. A second regulatory win arrived just days earlier in China, where Sevabertinib was authorized for first-line treatment of adults with advanced HER2-mutated non-small cell lung cancer. Should investors...
Keep reading with a free account
The rest of this article, and every signal for Bayer, is in your free account.
